Synopsys:
Godavari Biorefineries Ltd. announced that the China National Intellectual Property Administration (CNIPA) has granted it a patent for a cancer treatment.
The shares of this small-cap stock that engaged in the business of offering bio-based Chemicals, pharmaceuticals, and others are in focus after getting approval for compounds used for cancer treatment.
With a market capitalization of Rs. 1,543 Crores, the shares of Godavari Biorefineries Limited opened at Rs. 301.50 per equity share, from its previous day’s closing price of Rs. 287.15.
Patent Details
Godavari Biorefineries Limited has received a significant boost with the grant of a new patent by the China National Intellectual Property Administration (CNIPA). The patent, titled “5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER”, covers a novel compound found to be effective in fighting cancer and cancer stem cells. In laboratory (in vitro) studies, this compound has shown strong results against various cancer types, particularly breast and prostate cancers.
This development is a major milestone for Godavari Biorefineries, as it strengthens the company’s position in advanced healthcare research and biotechnology. This achievement reflects Godavari’s commitment to developing impactful, science-driven solutions that can benefit both patients and the business.
Company details
Godavari Biorefineries (GBL) is one of India’s largest ethanol producers and a pioneer in ethanol-based chemicals, using sugarcane as feedstock. Their products, including bio-based chemicals, ethanol, sugar, and power, serve industries like food and beverage, pharmaceuticals, flavours & fragrances, cosmetics, fuel, and power.
In Q4 FY25 the company earned most of its revenue from the distillery business(42 percent), followed by sugar and co-generation(33 percent) and bio based chemicals (24 percent). This shows the company has a well diversified business model.
The company’s revenue from operations surged from Rs. 1,687 crores in FY24 reaching Rs. 1,870 crores in FY25, reflecting strong business growth. The company reported a net profit of Rs.12 crore in FY24 but recorded a net loss of Rs.23 crore in FY25.
Written by Sudeep Kumbar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
